Viral conjunctivitis is characterized by the reddish eye, watery discharge from eye, and itching/irritation. Persistent conjunctivitis from virus may lead to corneal keratitis. Treatment for viral conjunctivitis may be symptomatic or virus specific.
Treatment can include artificial tear drops to lower the dryness and irritation from infection, vasoconstrictors to reduce eye redness, decongestants to reduce the swelling, and antihistamines to reduce itching. Treatments usually are continued for one to two weeks, depending on the severity of the infection. Anti-viral therapy is utilized to treat infections from herpes simplex and varicella zoster virus.
Increasing investment for development of new drugs to treat the viral conjunctivitis are further expected to propel the viral conjunctivitis drugs market growth. For instance, APD-209 is a drug candidate from Adenovir Pharma AB to treat epidemic keratoconjunctivitis from adenovirus, which has completed the phase 2 clinical studies in 2016. There is also increased awareness amongst patients about approaching the ophthalmologist to treat viral conjunctivitis.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1281
Viral Conjunctivitis Drugs Market report 2016-2020 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Viral Conjunctivitis Drugs market research report is a professional and in-depth study on the current state of Viral Conjunctivitis Drugs Industry.
Viral Conjunctivitis Drugs market report provides key statistics on the market status of the Viral Conjunctivitis Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Viral Conjunctivitis Drugs industry. The Viral Conjunctivitis Drugs market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market.
Key Vendors of Viral Conjunctivitis Drugs Market: Key players operating in the viral conjunctivitis drugs market include Bausch & Lomb, Allergan plc, Shire plc, NicOx S.A, NovaBay Pharmaceuticals, Inc., NanoViricides, Inc., Novartis International AG, Adenovir Pharma AB, Panoptes Pharma GES.M.B.H., Akorn Pharmaceuticals, and Quidel Corporation. Market players are investing in research to development of novel therapies to treat viral conjunctivitis.
Request for complete TOC of this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1281
Viral Conjunctivitis Drugs market report analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios.
Regions of Viral Conjunctivitis Drugs market:
In the end, the report makes some important proposals for a new project of Viral Conjunctivitis Drugs Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2016-2020 global Viral Conjunctivitis Drugs industry covering all important parameters.
Viral Conjunctivitis Drugs driver
Viral Conjunctivitis Drugs challenge
Viral Conjunctivitis Drugs trend
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1281